ArticleThe Pan African medical journal2025
Magnitude and trends of
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: tuberculosis (TB) is among the world´s top 10 infectious diseases, causing 1.5 million deaths annually, mostly in low-income countries. This study aimed to evaluate the magnitude and trends of Mycobacterium tuberculosis in Hargeisa, Somaliland. Methods: data from 18,280 presumptive TB clients enrolled between January 2020 and December 2023 at Hargeisa TB Hospital were analyzed using the GeneXpert Mycobacterium tuberculosis resistant to rifampicin assay. Data were entered into Excel, analyzed with SPSS v27, and assessed using Chi-square tests. Logistic regression was performed to estimate Adjusted Odds Ratios (AOR) with 95% Confidence Intervals (CI). Results: a total of 18,280 presumptive tuberculosis (TB) patients were included, with a mean age of 38.7 ± 20.2 years. Males accounted for 62.5% of the study population. Overall, 1,614 patients (8.8%) tested positive for TB. TB prevalence was higher in males (6.2%) than in females (2.6%), with males having greater odds of detection (adjusted odds ratio (AOR) 1.55; 95% CI: 1.38-1.73; p<0.001). Rifampicin resistance was identified in 43 cases (2.7%), more frequently in males (1.7%) than females (1.0%). TB detection declined from 10.2% in 2020 to 7.2% in 2023. The likelihood of rifampicin resistance was significantly higher in 2021-2023 compared with 2020 (AOR 9.29; 95% CI: 2.10-41.06; p<0.001 for 2021). Conclusion: the study revealed a significant burden of tuberculosis (TB) among presumptive pulmonary cases, with rifampicin resistance observed among confirmed patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.